GondolaBio and Children's Tumor Foundation are partnering on a preclinical NF1 programme, with patient expertise and programme equity at the centre of the deal.
FDA grants Priority Review to oral infigratinib after positive PROPEL 3 achondroplasia results, setting a February 4, 2027 decision.
BridgeBio reports new BBP-418 cardiac data in LGMD2I/R9 as the oral therapy approaches a November 27 FDA decision.
BridgeBio Pharma, Inc.’s BBP-418 wins FDA Priority Review for LGMD2I/R9. Discover what this could mean for rare muscular dystrophy treatment.
Explore how BridgeBio Pharma, Inc.’s Phase 3 CALIBRATE data could transform ADH1 treatment and reshape rare endocrine care. Read more now.
BridgeBio Pharma reports Phase 3 BBP-418 results and prepares FDA filing. Could this become the first therapy for limb-girdle muscular dystrophy?